Document is current
Any future updates will be listed below
-
Authors
Mitsi, Elena https://orcid.org/0000-0001-7586-6050
Diniz, Mariana O.
Reiné, Jesús
Collins, Andrea M.
Robinson, Ryan E.
Hyder-Wright, Angela
Farrar, Madlen
Liatsikos, Konstantinos https://orcid.org/0000-0003-2061-8329
Hamilton, Josh https://orcid.org/0000-0002-8523-3326
Onyema, Onyia
Urban, Britta C.
Solórzano, Carla
Belij-Rammerstorfer, Sandra
Sheehan, Emma
Lambe, Teresa https://orcid.org/0000-0001-7711-897X
Draper, Simon J. https://orcid.org/0000-0002-9415-1357
Weiskopf, Daniela
Sette, Alessandro https://orcid.org/0000-0001-7013-2250
Maini, Mala K. https://orcid.org/0000-0001-6384-1462
Ferreira, Daniela M. https://orcid.org/0000-0002-0594-0902
-
Funding
Funding for this research was provided by:
RCUK | Engineering and Physical Sciences Research Council (EP/W016389/1)
Bill and Melinda Gates Foundation (OPP1117728)
RCUK | Medical Research Council (M011569/1)
Foundation for the National Institutes of Health (75N9301900065)
Wellcome Trust (214191/Z/18/Z)
- License Information
-
More Information
Article History
Received: 14 July 2023
Accepted: 10 October 2023
First Online: 26 October 2023
Competing interests
: A.S. is a consultant for Gritstone Bio, Flow Pharma, Moderna, AstraZeneca, Qiagen, Fortress, Gilead, Sanofi, Merck, RiverVest, MedaCorp, Turnstone, NA Vaccine Institute, Emervax, Gerson Lehrman Group and Guggenheim. La Jolla Institute has filed for patent protection for various aspects of T cell epitope and vaccine design work. The remaining authors declare no competing interests.
